Clinton 2003 Abstract
Clinton 2003 Abstract
Clinton 2003 Abstract
gov/pubmed/12724928
Format: Abstract
A comparative study of four serological tumor markers for the detection of breast cancer.
Clinton SR1 , Beason KL, Bryant S, Johnson JT, Jackson M, Wilson C, Holifield K, Vincent C, Hall M.
Author information
Abstract
Breast cancer is currently the third most common cause of cancer in the world. Circulating tumor antigens are often used as a
minimally invasive tool for noting breast cancer progression. The objective of this study was to compare four tumor antigens (CA
15-3, CA 27.29, alpha-fetoprotein [AFP], and carcinoembryonic antigen [CEA]) for their diagnostic efficacy in breast cancer
patients. It was hypothesized that CA 15-3 would proved to be superior to CA 27.29, CEA, and AFP in assay performance. Tumor
marker assays were performed according to the manufacturers' directions. Assays used in this study were CA 15-3 and CA 27.29
(Fujirebio Diagnostics/Centocor Inc.), AFP (Abbott Inc.), and CEA (Hybritech Inc.). A total of 554 patient samples were obtained
from an area hospital, plus 200 healthy adult samples which were used for the determination of normal reference intervals. The
patients included patients with no disease (184), with non-malignant disease (11), with breast cancer (87), and with other types of
cancer (272). Diagnostic percent sensitivities for each marker were: CA 15-3 (63%), CA 27.29 (39%), CEA (22%), and AFP (22%).
Diagnostic specificities for each marker were comparable, ranging from 80-88%. Analytical parameters were evaluated for the
assays and compared favorably. We concluded that CA 15-3 was the best tumor antigen for use as a diagnostic aid and monitoring
agent.
PMID: 12724928
[Indexed for MEDLINE]
1 of 1 22-12-2018, 19:47